
Sign up to save your podcasts
Or
TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with two distinguished experts about new heart failure guidelines.
Listen in as they discuss new guidelines for managing heart failure with reduced ejection fraction (HFrEF)...and put this new guidance in perspective.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Carolyn Lam reports relevant financial relationships with Bayer, Roche Diagnostics (grants/research support); Abbott, Actelion, Alleviant Medical, Allysta Pharmaceuticals, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceuticals, Janssen, Merck, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, Us2.ai (advisory board/steering committee/executive committee); Us2.ai (stock shareholder); Us2.ai (non-executive director).
Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support).
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com.
Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at [email protected].
4.3
4646 ratings
TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with two distinguished experts about new heart failure guidelines.
Listen in as they discuss new guidelines for managing heart failure with reduced ejection fraction (HFrEF)...and put this new guidance in perspective.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Carolyn Lam reports relevant financial relationships with Bayer, Roche Diagnostics (grants/research support); Abbott, Actelion, Alleviant Medical, Allysta Pharmaceuticals, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceuticals, Janssen, Merck, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, Us2.ai (advisory board/steering committee/executive committee); Us2.ai (stock shareholder); Us2.ai (non-executive director).
Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support).
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com.
Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at [email protected].
534 Listeners
98 Listeners
481 Listeners
687 Listeners
254 Listeners
3,330 Listeners
21 Listeners
1,365 Listeners
1,095 Listeners
693 Listeners
151 Listeners
362 Listeners
36 Listeners
5 Listeners
4 Listeners